Investors concerned about a double-dip can shield themselves with large-cap companies that have global reach and ample cash to withstand a slowdown.
Celgene now has a total of 17 ‘buy’ ratings and just 2 ‘hold’ ratings. Why are so many analysts so bullish?
Chatter that a major drug maker is looking to make at least one if not several acquisitions sent biotech surging. What must you know?
Corporations hold large amounts of cash for a variety of reasons. So, which S&P 500 companies are the most cash-rich? Click to find out!
Stocks ended their worst quarter in over a year with a selloff Wednesday after a disappointing report on private-sector employment in the U.S. Banks ended mostly lower. Ford jumped.
What follows is a look at stocks in the S&P 500 displaying unusual volume in today's trading session.
Stocks oscillated Wednesday as investors juggled some encouraging bank news against a disappointing report on private-sector employment in the U.S. Ford jumped.
Stocks turned higher Wednesday as investors juggled some encouraging bank news from Europe against a disappointing report on private-sector employment in the U.S.
Wall Street looked set for a slightly lower opening Wednesday after the latest report on private-sector employment arrived much weaker than expected.
Another late selling jag sent the S&P lower on Monday. What's next? Watching 3 stocks could give you a leg up.
Stocks fell sharply after a late selloff Monday after a report showed consumer credit rose slightly. Industrials, financials and tech were the weakest links.
Drug developer Celgene is expected to release data on from two studies in coming weeks, and the bulls are looking for a rally.
Following are the week’s biggest winners and losers. Find out why shares of Baidu and Celgene popped while Citigroup and Green Mountain Coffee dropped.
Following are moves you might have missed. Find out why shares of Baidu and Kellogg popped while Eastman Kodak and Apollo Group dropped.
Plus, get another drilling play from Cramer and his call on Caterpillar.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Following are movers you might have missed. Find out why shares of Manitowoc and Royal Caribbean popped while Clean Energy Fuels and Celgene dropped.
If you’re a biotech investor this week could be one for the history books.
Last Sunday, the House passed a historic $938 billion health care bill and on Tuesday, President Obama signed the bill into law. The Senate will try to pass a second measure passed by the House on Sunday amending portions of the bill through a process called reconciliation. This massive health care overhaul is expected to guarantee insurance coverage for 32 million uninsured Americans. The cost of covering these currently uninsured citizens is expected to be covered by a combination of taxes on wealthy individuals and companies and through Medicare cost cuts.
The iShares Nasdaq Biotechnology Index Fund is up 11 percent so far in 2010.